Aceclidine - Lenz Therapeutics
Alternative Names: LNZ-100Latest Information Update: 30 Oct 2024
Price :
$50 *
At a glance
- Originator LENZ Therapeutics
- Developer Corxel Pharmaceuticals; LENZ Therapeutics
- Class Antiglaucomas; Azabicyclo compounds; Eye disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Presbyopia